Keyphrases
Acquired Resistance
40%
Armamentarium
20%
Aromatase Inhibition
20%
Clinical Application
20%
Cyclin-dependent Kinase 6 (CDK6)
20%
Endocrine Therapy
100%
ER Signaling
20%
ER-targeting
20%
Estrogen Biosynthesis
20%
Estrogen Receptor 1 (ESR1)
40%
Estrogen Receptor Pathway
100%
Estrogen Receptor-positive Breast Cancer
20%
Estrogen Receptor-positive Metastatic Breast Cancer
100%
Everolimus
20%
First-line Systemic Therapy
20%
Genomic Studies
20%
Hormone Levels
20%
Intrinsic Resistance
20%
Mammalian Target of Rapamycin Pathway
20%
MTOR Inhibitor
20%
Multiple Combinations
20%
Multiple Levels
20%
Multiple Lines
20%
Phosphoinositide 3-kinase (PI3K)
20%
Postmenopausal Women
100%
Receptor Downregulation
20%
Receptor Modulation
20%
Recurrent mutation
20%
Resistance Mechanisms
20%
Resistance to Endocrine Therapy
40%
Selective Estrogen Receptor Modulators
40%
Therapeutic Target
20%
Therapy Approaches
20%
Treatment Modalities
20%
Medicine and Dentistry
Aromatase
14%
Cyclin-Dependent Kinase 4
14%
Estrogen Receptor
100%
Estrogen Receptor Alpha
28%
Estrogen Receptor Positive Breast Cancer
14%
Estrogen Synthesis
14%
Everolimus
14%
Hormone Determination
14%
Hormone Therapy
100%
Mammalian Target of Rapamycin Inhibitor
14%
Mechanistic Target of Rapamycin
14%
Metastatic Breast Cancer
100%
Phosphoinositide 3-Kinase
14%
Postmenopause
100%
Receptor down Regulation
14%
Receptor Modulation
14%
Systemic Therapy
14%
Pharmacology, Toxicology and Pharmaceutical Science
Aromatase
14%
Cyclin Dependent Kinase 4
14%
Endocrine Therapy
100%
Estrogen Receptor
100%
Estrogen Receptor Alpha
28%
Estrogen Receptor Positive Breast Cancer
14%
Everolimus
14%
Mammalian Target of Rapamycin
14%
Mammalian Target of Rapamycin Inhibitor
14%
Metastatic Breast Cancer
100%
Phosphatidylinositol 3 Kinase
14%